Announcement of TTY Biopharm's unaudited income information in January 2025

2025.2.10

Provided by: TTY BIOPHARM COMPANY LIMITED
SEQ_NO 1 Date of announcement 2025/02/10 Time of announcement 17:00:59
Subject Announcement of TTY Biopharm's unaudited income information in January 2025
Date of events 2025/02/10 To which item it meets paragraph 53
Statement 1.Date of occurrence of the event:2025/02/10
2.Company name:TTY Biopharm Co., Ltd.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $
482,990 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $135,604 thousands, and a consolidated income before tax of $188,911 thousands in January 2025; net income attributed to stockholders of the company was $145,633 thousands; EPS is $0.59.
Year-to-date consolidated net sales was $
482,990 thousands (in NT dollars; unaudited), a consolidated operating profit was $135,604 thousands and consolidated income before tax was $188,911 thousands until January 2025; year-to-date net income attributed to stockholders of the company was $145,633 thousands; EPS is $0.59.
6.Countermeasures:None.
7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail.
TOP